EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer

Stephanie L Graff, Fengting Yan, Yara Abdou

Clinical Breast Cancer · 2023-10 · 23 (7) · e380-e393

DOI: 10.1016/j.clbc.2023.05.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Breast Cancer, 2023-10. Verfasst von Stephanie L Graff und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ambulatory Patient Center, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University, Rhode Island Hospital, Providence, RI. Electronic …. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca, Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) is an aggressive tumor type, accounting for 15% to 20% of the approximately 300,000 new BC cases in the United States each year. The goal of this review is to discuss the evolving landscape of therapies for HER2+ metastatic BC (mBC). Targeted therapies that have been the standard of care (SOC) for HER2+ mBC for almost a decade have greatly improved patient outcomes. The SOC for the first-line treatment of HER2+ mBC continues to be HER2-targeted monoclonal antibodies (mAbs) + a taxane, but recent updates in the second-line setting favor use of a newer HER2-targeted antibody-drug conjugate (ADC), trastuzumab deruxtecan, versus the prior SOC ADC, trastuzumab emtansine. Numerous options are now available in the third line and beyond, including tyrosine kinase inhibitor (TKI) regimens, newer mAbs, and other ADCs. The optimal course of treatment for individual patients can be guided by location of metastases, prior therapies, concomitant biomarkers, and monitoring and management of adverse events. Ongoing trials will further the evolution of the HER2+ mBC treatment landscape. Furthermore, next-generation ADCs, TKIs, and classes of drugs that have not been approved for the treatment of HER2+ mBC, including immune checkpoint inhibitors and cyclin-dependent kinase 4 and 6 inhibitors, are also being evaluated for their efficacy in the first and second line. Although the influx of new drugs may complicate treatment decisions for physicians, having a multitude of options will undoubtedly further improve patient outcomes and patient-centered care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic AgentsHumansFemaleErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedTrastuzumabAdo-Trastuzumab Emtansine

Stichwörter der Autor:innen

Antibody-drug conjugateHER2Monoclonal antibodyStandard of careTyrosine kinase inhibitor

Substanzen

Antineoplastic AgentsErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedTrastuzumabAdo-Trastuzumab Emtansine

Autor:innen und Institutionen

  • Ambulatory Patient Center, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University, Rhode Island Hospital, Providence, RI. Electronic address: SGraff1@Lifespan.org.
  • Swedish Cancer Institute, First Hill-True Family Women's Cancer Center, Seattle, WA.
  • UNC School of Medicine, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC.

Förderung

  • AstraZeneca
  • Daiichi-Sankyo

Zitieren

APA

Graff, S. L., Yan, F., & Abdou, Y. (2023). Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer, 23(7), e380-e393. https://doi.org/10.1016/j.clbc.2023.05.003

Vancouver

Graff SL, Yan F, Abdou Y. Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer. 2023;23(7):e380-e393. doi:10.1016/j.clbc.2023.05.003

BibTeX
@article{Graff2023,
  author = {Graff, Stephanie L and Yan, Fengting and Abdou, Yara},
  title = {Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer},
  journal = {Clinical Breast Cancer},
  year = {2023},
  volume = {23},
  number = {7},
  pages = {e380--e393},
  doi = {10.1016/j.clbc.2023.05.003}
}
Kostenlos starten →